Ionis Price To Sales Ratio from 2010 to 2024
IONS Stock | USD 33.94 1.46 4.12% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 9.19699066 | Current Value 15.6 | Quarterly Volatility 9.71809226 |
Check Ionis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ionis Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 23.6 M, Interest Expense of 85.5 M or Total Revenue of 827 M, as well as many indicators such as Price To Sales Ratio of 15.6, Dividend Yield of 0.0 or PTB Ratio of 17.8. Ionis financial statements analysis is a perfect complement when working with Ionis Pharmaceuticals Valuation or Volatility modules.
Ionis | Price To Sales Ratio |
Latest Ionis Pharmaceuticals' Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of Ionis Pharmaceuticals over the last few years. Price to Sales Ratio is figured by comparing Ionis Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Ionis Pharmaceuticals sales, a figure that is much harder to manipulate than other Ionis Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Ionis Pharmaceuticals' Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ionis Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
View | Last Reported 6.67 X | 10 Years Trend |
|
Price To Sales Ratio |
Timeline |
Ionis Price To Sales Ratio Regression Statistics
Arithmetic Mean | 15.87 | |
Geometric Mean | 13.47 | |
Coefficient Of Variation | 61.25 | |
Mean Deviation | 7.91 | |
Median | 11.93 | |
Standard Deviation | 9.72 | |
Sample Variance | 94.44 | |
Range | 28.631 | |
R-Value | (0.52) | |
Mean Square Error | 73.68 | |
R-Squared | 0.28 | |
Significance | 0.04 | |
Slope | (1.14) | |
Total Sum of Squares | 1,322 |
Ionis Price To Sales Ratio History
About Ionis Pharmaceuticals Financial Statements
Ionis Pharmaceuticals shareholders use historical fundamental indicators, such as Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Although Ionis Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Ionis Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Ionis Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last Reported | Projected for Next Year | ||
Price To Sales Ratio | 9.20 | 15.60 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Ionis Stock Analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.